Cocrystal Pharma (NASDAQ:COCP – Get Rating) and FibroGen (NASDAQ:FGEN – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.
Earnings and Valuation
This table compares Cocrystal Pharma and FibroGen’s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cocrystal Pharma | $2.01 million | 10.19 | -$38.84 million | ($4.73) | -0.53 |
| FibroGen | $140.73 million | 12.53 | -$293.65 million | ($3.14) | -5.96 |
Cocrystal Pharma has higher earnings, but lower revenue than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
Profitability
This table compares Cocrystal Pharma and FibroGen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cocrystal Pharma | N/A | -35.16% | -33.88% |
| FibroGen | -208.66% | -338.94% | -44.30% |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Cocrystal Pharma and FibroGen, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cocrystal Pharma | 0 | 0 | 2 | 0 | 3.00 |
| FibroGen | 1 | 1 | 3 | 0 | 2.40 |
FibroGen has a consensus target price of $23.40, indicating a potential upside of 25.00%. Given FibroGen’s higher possible upside, analysts plainly believe FibroGen is more favorable than Cocrystal Pharma.
Risk and Volatility
Cocrystal Pharma has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.
Summary
Cocrystal Pharma beats FibroGen on 8 of the 14 factors compared between the two stocks.
About Cocrystal Pharma
Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded in 2008 and is headquartered in Bothell, WA.
About FibroGen
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
